Shares of the Medicines Co. got knocked around after the Parsippany, N.J.-based firm halted two massive Phase III trials of antiplatelet agent cangrelor, eliminating the chances of a 2010 product launch to stave off an expected revenue decline when its top-selling drug, Angiomax, goes off patent next year. (BioWorld Today) Read More
